-
COVID-19 Is Reshaping Global Pharmaceutical Competition – to Asia’s Benefit
09 Oct 2021 22:45 GMT
… American and European pharmaceutical firms benefited from relatively open access to … clinical trials. Likewise, Japan’s Daiichi Sankyo has a production agreement with … synergies and spillover effects that benefit the development of treatments targeting …
-
AstraZeneca, Daiichi Sankyo announce positive results from phase III DESTINY─Breast03 trial of Enhertu vs trastuzumab emtansine in patients with HER2─positive metastatic breast cancer
10 Aug 2021 05:31 GMT
… deruxtecan), the AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) HER2-directed antibody drug … future opportunities to bring this benefit to patients in earlier … rate, duration of response, clinical benefit rate, PFS based on investigator …
-
Atrial Fibrillation Drugs Market Analysis and Forecast 2021: By Top Keyplayers Johnson & Johnson, Pfizer, Sanofi, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo and AstraZeneca. | ARC
14 Jul 2021 04:12 GMT
… the forecast period, which can benefit the user for taking the … , Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo and AstraZeneca. Overview of the … , Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo and AstraZeneca. | ARC appeared first …
-
STEMI Latecomers Still Benefit From Coronary Revascularization
22 Sep 2021 19:00 GMT
… 12 hours still derive significant benefit from coronary revascularization of the … , Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp and …
-
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
20 Sep 2021 20:41 GMT
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor tests.
What Happened: The Phase 3 DESTINY-Breast03 head-to-head study included second-line …
-
Daiichi Sankyo receives Japanese approval for Delytact to treat malignant glioma
12 Jun 2021 07:26 GMT
… of primary brain cancer. Daiichi Sankyo has been collaboratively developing Delytact … amp;D Division in Japan, Daiichi Sankyo. “Delytact is the fourth … approved in Japan for Daiichi Sankyo over the past two … and description of clinical benefit and safety in a …
-
Alzheimer’s Therapeutics Market Analysis, Segments, Size, Share, Industry Growth and Recent Trends by Forecast to 2028
02 Dec 2021 08:33 GMT
… are:
Eli Lilly and Company, Daiichi Sankyo Hoffmann-La Roche Ltd, Pfizer … players in the market.
Key Benefits of the Global Alzheimer…
-
Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
26 Apr 2021 20:02 GMT
… a licensing agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) providing Daiichi Sankyo with exclusive rights … allows Esperion to benefit from the commercial strength of Daiichi Sankyo group in …
-
EMA committee recommends conditional marketing approval for Daiichi Sankyo & AstraZeneca's trastuzumab deruxtecan to treat HER2 positive breast cancer
15 Dec 2020 04:17 GMT
… development, oncology R&D, Daiichi Sankyo. “Trastuzumab deruxtecan is already available … response, disease control rate, clinical benefit rate, progression-free survival and … conjugate (ADC). Designed using Daiichi Sankyo’s proprietary DXd ADC technology …
-
Daiichi Sankyo enters clinical collaboration with AstraZeneca to evaluate patritumab deruxtecan in combo with Tagrisso in EGFR─mutated NSCLC
08 Aug 2020 10:49 GMT
… development, oncology R&D, Daiichi Sankyo. “This clinical trial collaboration supports … work to continue maximizing the benefit Tagrisso can bring to patients … been established.
The mission of Daiichi Sankyo Cancer Enterprise is to leverage …
About
© 1995-2021